Shenzhen Salubris Pharmaceuticals Co Ltd - Asset Resilience Ratio
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has an Asset Resilience Ratio of 4.97% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Shenzhen Salubris Pharmaceuticals Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Shenzhen Salubris Pharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See Shenzhen Salubris Pharmaceuticals Co Ltd (002294) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Salubris Pharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shenzhen Salubris Pharmaceuticals Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥545.66 Million | 4.97% |
| Total Liquid Assets | CN¥545.66 Million | 4.97% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen Salubris Pharmaceuticals Co Ltd maintains only 4.97% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Salubris Pharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shenzhen Salubris Pharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Shenzhen Salubris Pharmaceuticals Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Shenzhen Salubris Pharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.01% | CN¥733.86 Million ≈ $107.39 Million |
CN¥10.47 Billion ≈ $1.53 Billion |
-2.37pp |
| 2023-12-31 | 9.38% | CN¥881.57 Million ≈ $129.00 Million |
CN¥9.40 Billion ≈ $1.38 Billion |
+6.02pp |
| 2022-12-31 | 3.37% | CN¥328.36 Million ≈ $48.05 Million |
CN¥9.76 Billion ≈ $1.43 Billion |
+2.72pp |
| 2021-12-31 | 0.65% | CN¥60.00 Million ≈ $8.78 Million |
CN¥9.24 Billion ≈ $1.35 Billion |
-2.45pp |
| 2020-12-31 | 3.10% | CN¥214.59 Million ≈ $31.40 Million |
CN¥6.92 Billion ≈ $1.01 Billion |
+0.41pp |
| 2019-12-31 | 2.69% | CN¥208.00 Million ≈ $30.44 Million |
CN¥7.73 Billion ≈ $1.13 Billion |
-4.90pp |
| 2018-12-31 | 7.59% | CN¥600.00 Million ≈ $87.80 Million |
CN¥7.90 Billion ≈ $1.16 Billion |
-4.79pp |
| 2017-12-31 | 12.38% | CN¥850.00 Million ≈ $124.38 Million |
CN¥6.86 Billion ≈ $1.00 Billion |
+11.39pp |
| 2016-12-31 | 0.99% | CN¥65.00 Million ≈ $9.51 Million |
CN¥6.53 Billion ≈ $956.15 Million |
+0.62pp |
| 2015-12-31 | 0.37% | CN¥20.00 Million ≈ $2.93 Million |
CN¥5.39 Billion ≈ $788.27 Million |
-4.18pp |
| 2014-12-31 | 4.55% | CN¥210.00 Million ≈ $30.73 Million |
CN¥4.62 Billion ≈ $675.47 Million |
-- |
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more